PALYNZIQ^®(pegvaliase) Injection

GIVE YOUR PATIENTS WITH PKU

A difference they can see in Phe

PALYNZIQ^® is the first and only approved enzyme substitution therapy for patients 16 years and older with phenylketonuria (PKU) who have blood phenylalanine (Phe) levels >600 µmol/L.¹

In clinical trials, patients experienced reductions in blood Phe levels over a 36-month period.¹

72% of patients reached blood Phe levels ≤600 µmol/L within the 36-month period¹

PALYNZIQ is the first and only enzyme therapy to address the underlying cause of phenylketonuria (PKU).¹

In clinical trials, PALYNZIQ achieved significant reductions in blood Phe levels.¹

INDICATION
PALYNZIQ^® is indicated for the treatment of patients with phenylketonuria (PKU) 16 years and older who have inadequate blood Phe control (blood Phe levels greater than 600 µmol/L) despite prior management with available treatment options.¹
^▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See full Summary of Product Characteristics for more information.